Founded by pharmaceutical and legal executive Larry Raoul James, MindLab is a pain-therapy company developing treatments intended to deliver morphine-level relief with less risk of abuse-related harm. Its work centers on MLB-001, a proposed morphine replacement for patients who need effective pain control without the consequences associated with conventional opioid therapy.
GLP-certified facilities
CLIA-certified facilities
GLP
Quality certification
MAXONA Pharmaceuticals, IncMAXONA Pharmaceuticals is a clinical-stage drug developer advancing MAX-001, a patent-protected, non-opioid and non-NSAID treatment candidate for acute and chronic pain. Founded by President and CEO Shawn Fatholahi, the company draws on a leadership team with deep experience in neuroscience, formulation, clinical development and regulatory affairs. MAX-001 has completed its IND-enabling studies and Phase I trials, with Phase II development expected to be completed in 2026.MALVERN, PA
Egalet CorporationEgalet Corporation is a fully integrated specialty pharmaceutical company developing and commercializing medicines for acute and chronic pain, with a particular focus on oral products designed to deter prescription-drug abuse. Its Guardian Technology uses physical and chemical barriers alongside tailored drug release, while the company’s manufacturing approach combines pharmaceutical production with plastic injection molding. Egalet has marketed OXAYDO and SPRIX and has described late-stage abuse-deterrent opioid candidates in its pipeline.WAYNE, PA
CriterionMedFounded in 1993 by Dr. Langheier, CriterionMed develops electromedical devices and other non-invasive solutions for chronic pain management and rehabilitation. The company carries a family medical tradition reaching back to 1884 and says its products have treated more than 150,000 patients since 2002, helping people manage pain at home without relying solely on prescription drugs.NEW YORK, NY
PleoPharma, IncFounded in 2019 by physicians Ginger and Jay Constantine, PleoPharma develops pharmaceutical treatments for substance use disorders, beginning with an investigational oral therapy for cannabis withdrawal. The Phoenixville-based company emerged after the founders saw patients struggling to stop cannabis use and discovered that no effective treatment existed; its lead program, PP-01, has completed Phase 2.PHOENIXVILLE, PA